On March 15, 2017, BioSig Technologies, Inc. (the “Company”) entered into a know-how license agreement (the “Agreement”) with Mayo Foundation for Medical Education and Research (“Mayo”). The Agreement grants a non-exclusive license to the Company to use research and development information, materials, technical data, unpatented inventions, trade secrets, know-how and supportive information related to the licensed products (“Licensed Products”) described in the Agreement, and an exclusive license to the Company to use, develop, make, sell and import the Licensed Products.

In connection with the Agreement, the Company issued to Mayo a three-year cash warrant (the “Warrant”) to purchase 630,000 shares of the Company’s common stock at an exercise price of $1.50. The Company also agreed to pay earned royalty payments to Mayo in connection with the Company’s sales of the Licensed Products to third parties.

Item 3.02 Unregistered Sales of Equity Securities

In connection with the Agreement described in item 1.01 above, the Company issued the Warrant to Mayo to purchase 630,000 shares of the Company’s common stock. Such issuance of the Warrant was not registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state, and was issued in reliance on the exemption from registration under the Securities Act provided by Section 4(a)(2) under the Securities Act.

The other information called for by this item is contained in Item 1.01, which is incorporated herein by reference.

About BioSig Technologies, Inc. (OTCMKTS:BSGM)

BioSig Technologies, Inc. is a development-stage medical device company. The Company is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System. PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The Company’s PURE EP System is designed to assist electrophysiologists with real-time evaluations of electrocardiograms and electrograms, and helps in making clinical decisions in real-time. It is also developing signal-processing tools, which will assist electrophysiologists in differentiating true signals from noise and provide guidance in identifying ablation targets within the PURE EP System.

BioSig Technologies, Inc. (OTCMKTS:BSGM) Recent Trading Information

BioSig Technologies, Inc. (OTCMKTS:BSGM) closed its last trading session up +0.20 at 1.65 with 65,794 shares trading hands.